

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	MAIL STOP
)	
Masashi ISOZAKI et al.)	Group Art Unit: 1633
)	
Application No.: 10/594,427)	Examiner: James SCHULTZ
)	
Filed: July 17, 2008)	Confirmation No.: 2940
)	
For: LIPOSOME PREPARATION)	
)	
)	
)	
)	
)	

THIRD INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), a statement is enclosed.

The references are cited in an Office Action dated October 12, 2011, in corresponding Korean Patent application No. 10-2006-7019769. A copy of the Office Action and a partial English Translation thereof are being submitted herewith.

CERTIFICATION UNDER 37 C.F.R. §1.97(e)

I, the undersigned, hereby state in accordance with 37 C.F.R. § 1.97(e)(1) that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement.


To assist the Examiner, the documents are listed on the attached form PTO/US/08. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: December 20, 2011

By: 
Matthew L. Schneider
Registration No. 32,814

Customer No. 21839
703 836 6620